A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. [electronic resource]
Producer: 20130426Description: 1301-9 p. digitalISSN:- 2040-2058
- Adult
- Aged
- Antiretroviral Therapy, Highly Active -- methods
- Biomarkers -- metabolism
- CD4-CD8 Ratio
- CD4-Positive T-Lymphocytes -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Chemokine CCL5 -- metabolism
- Disease Progression
- Female
- HIV Infections -- drug therapy
- HIV-1 -- pathogenicity
- Humans
- Immunologic Memory
- Inflammation -- immunology
- Inflammation Mediators -- immunology
- Lymphocyte Activation
- Male
- Middle Aged
- Pilot Projects
- Pyrrolidinones -- pharmacology
- Raltegravir Potassium
- Viral Load
- gag Gene Products, Human Immunodeficiency Virus -- immunology
- nef Gene Products, Human Immunodeficiency Virus -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.